Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
13.52B
Market cap13.52B
Price-Earnings ratio
-38.91
Price-Earnings ratio-38.91
Dividend yield
Dividend yield
Average volume
2.42M
Average volume2.42M
High today
$81.99
High today$81.99
Low today
$79.11
Low today$79.11
Open price
$79.53
Open price$79.53
Volume
2.24M
Volume2.24M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$40.03
52 Week low$40.03

Stock Snapshot

With a market cap of 13.52B, Ionis Pharmaceuticals(IONS) trades at $81.80. The stock has a price-to-earnings ratio of -38.91.

On 2026-07-05, Ionis Pharmaceuticals(IONS) stock moved within a range of $79.11 to $81.99. With shares now at $81.80, the stock is trading +3.4% above its intraday low and -0.2% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 2.24M, versus its average volume of 2.42M.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

IONS News

Investing.com 4d
Ionis Pharmaceuticals EVP CLO sells $245,520 in stock - Investing.com

...

Ionis Pharmaceuticals EVP CLO sells $245,520 in stock - Investing.com
Simply Wall St 6d
Why Ionis Pharmaceuticals Is Up 9.5% After Dual TRYNGOLZA Approval and Zilganersen Out-Licensing Deal

Earlier this week, Ionis Pharmaceuticals announced that the FDA approved TRYNGOLZA (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults wit...

Why Ionis Pharmaceuticals Is Up 9.5% After Dual TRYNGOLZA Approval and Zilganersen Out-Licensing Deal

Analyst ratings

85%

of 27 ratings
Buy
85.2%
Hold
14.8%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.